CCL2 and hyperlipidemia: This interaction profile positions apigenin hexoside as a promising candidate for managing hyperlipidemia and related metabolic disorders.The interaction of quercetin acetyl rutinoside with Mcp1 yielded a binding energy of −8.6 kcal/mol (Table S4).